Xylazine CAS: 7361-61-7 CAS: 23076-35-9

CAS NO: 7361-61-7
Chemical Name: Xylazine
Molecular Formula: C12H16N2S
Formula Weight: 220.33
CAS No.: 7361-61-7
CAS:  23076-35-9
Description Review
Description
An effective muscle relaxant, analgesic, and sedative, xylazine is often used in veterinary medicine. Its broad usage in animal sedation emphasizes its importance in veterinary applications, particularly in the management of domestic and wild animals for different medical operations.

Xylazine CAS: 7361-61-7  CAS: 23076-35-9

Uses of xylazine, veterinary applications of xylazine, sedation with xylazine, recommended dosage of xylazine, potential side effects of xylazine,


  • xylazine veterinary use,
  • xylazine effects,
  • xylazine dosage for dogs,
  • xylazine side effects in animals,
  • xylazine legal status,
  • xylazine pharmacodynamics,
  • xylazine wildlife sedation,
  • how to reverse xylazine,
  • xylazine for sale,
  • xylazine in emergency medicine,

Comparable Competitive Products
Xylazine's main rivals in the veterinary tranquilizer market are Detomidine and Romifidine. Both of these drugs are also used to calm and ease the pain of different animal types.

Benefits for Your Health
The sedative and calming effects of xylazine have made it an indispensable tool in veterinary medicine for treatments requiring immobilization or substantial decrease of anxiety in animals.

Possible Consequences
Not only does Xylazine have a sedative effect, but it also has the ability to drop blood pressure and respiration rate, which is advantageous in medical settings that are under strict monitoring.


Product Mechanism
Xylazine, an α₂ adrenoceptor agonist, leads to drowsiness, muscular relaxation, and analgesia by suppressing norepinephrine release, reducing pain signals and central nervous system activity.

Ensuring safety
Because of its strong pharmacological effects, xylazine should always be administered by a certified veterinarian or under their supervision, even though it is safe when used as prescribed.

Potential adverse reactions
Potential adverse effects include bradycardia, respiratory depression, hypotension, and temporary hyperglycemia. Cultivating and overseeing these effects throughout usage is imperative.

Information on Dosage
How much Xylazine to give depends on the animal's species, how sedated it needs to be, and its health. Intravenous or intramuscular injections are the usual methods of administration.

Important considerations
Xylazine should not be administered to animals who have serious heart illness, respiratory problems, liver or renal ailments, or the combination of these conditions. Pregnant or lactating animals should not use it unless the advantages exceed the hazards.

In summary
Because of its effectiveness and adaptability in controlling sedation, xylazine is still a staple medication in veterinary care. Its continuous usage, under the right circumstances and doses, demonstrates its value in veterinary treatment. Nonetheless, strict regulatory oversight is imperative due to the substantial obstacles that can arise from the possibility of abuse and misuse in contexts other than veterinary medicine.

Additional Questions
Can you tell me the veterinary uses of Xylazine?
Xylazine is generally used for the purpose of sedating and relaxing animals in preparation for a variety of medical operations, such as surgical procedures, minor treatments, and diagnostic tests. This is done to assure the well-being of animals as well as the safety of veterinarians.

Are there long-term animal Xylazine negative effects?
When administered properly, long-term negative effects are usually not a problem with xylazine. However, continuous use or abuse may result in consequences such as tolerance, withdrawal symptoms, and more severe cardiovascular effects.


Can Xylazine be administered to every animal species?
Even though Xylazine can be used for many things, it is not good for all animal types. Because of the sensitivity of some species, such as sheep and goats, to its effects, the administration of this substance in these animals necessitates cautious dose modifications and close monitoring.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code